Floatz logo

Minnelide

Gastric Adenocarcinoma

Minneamrita Therapeutics LLCUNKNOWNPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

65 Active assets in the Gastric Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Fluorouracilum
Boehringer Ingelheim
Phase 3BB
Oxaliplatin
Shanghai Zhongshan Hospital
Phase 3BB
Trastuzumab
Boehringer Ingelheim
Phase 2BB
Cis-Diamminedichloroplatinum Ii
Mayo Clinic
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Minnelide is also rated in:

pancreatic adenosquamous carcinomaActive
B
Indicative · Phase 2
57 / 100
View asset →
pancreatic neoplasmDormant
CCC
Indicative · Phase 2
53 / 100
View asset →
colorectal cancerDormant
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →